Sarah Bricault

Dr. Sarah Bricault

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSarah Bricault
Sarah Bricault
MDMiranda Dawson
Miranda Dawson
JLJiyoung Lee
Jiyoung Lee
MDMitul Desai
Mitul Desai
MSMiriam Schwalm
Miriam Schwalm
AJAlan Jasanoff
Alan Jasanoff
The correlational structure of brain activity dynamics in the absence of stimuli or behavior is often taken to reveal intrinsic properties of neural function. To test the limits of this assumption, we analyzed peripheral contributions to resting state activity measured by fMRI in unanesthetized, chemically immobilized male rats that emulate human neuroimaging conditions. We find that perturbation of somatosensory input channels modifies correlation strengths that relate somatosensory areas both to one another and to higher-order brain regions, despite the absence of ostensible stimuli or movements. Resting state effects are mediated by the same peripheral and thalamic structures that relay responses to overt sensory stimuli. The impact of basal peripheral input is reduced in a rat model of autism, which displays both lower somatosensory functional connectivity and insensitivity to vibrissa inactivation. These results demonstrate the influence of extrinsic influences on resting state brain phenotypes in health and disease.

28 November 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RTRamya Tokala
Ramya Tokala
TPTorben D. Pearson
Torben D. Pearson
BMBraeden A. Mair
Braeden A. Mair
SBSarah Bricault
Sarah Bricault
RWRachel Wallace
Rachel Wallace
SLSo Jeong Lee
So Jeong Lee
Background/Objective: Acute and chronic pain affect millions of individuals, yet there are currently no molecular imaging tools to directly assess pain-related mechanisms in the central nervous system (CNS). The voltage-gated sodium channel NaV1.8 plays a pivotal role in neuropathic pain by increasing the excitability of nociceptive neurons following nerve injury or inflammation. In this work, we aimed to develop a novel positron emission tomography (PET) imaging probe for NaV1.8 to facilitate noninvasive quantification of this target in the CNS and thereby advance our understanding of pain neurobiology. Methods: We selected the compound suzetrigine, a U.S. FDA-approved, highly selective non-opioid NaV1.8 inhibitor, as the first candidate for a NaV1.8-targeted PET tracer. The compound was first assessed using in silico docking and CNS multiparameter optimization (MPO) analysis to evaluate target binding and predicted brain penetrability. Radiolabeling was accomplished by O-methylation with [11C]methyl iodide to yield [11C]suzetrigine without structural modification. The tracer was then evaluated using in vitro binding assays, including autoradiography and saturation binding on rat brain tissues, to determine binding parameters (KD, Bmax), and using in vivo PET imaging in rats to assess brain uptake, time–activity curves (TACs), and tracer behavior under baseline and pretreatment conditions. Pretreatment was performed with unlabeled suzetrigine, the P-glycoprotein (P-gp) inhibitor verapamil, and the heterologous NaV1.8 inhibitor A-803467. Results: In silico docking demonstrated favorable binding of suzetrigine to the NaV1.8 active site, and the calculated CNS MPO score (>3.5) suggested adequate brain penetration. Radiochemical synthesis of [11C]suzetrigine via O-methylation yielded a high decay-corrected radiochemical yield (19.2 ± 2.7%, n = 3), excellent purity (>98%, n = 3), and moderate molar activity (62.9 ± 51.8 MBq/nmol, n = 3). Autoradiography on rat brain tissue confirmed saturable and selective binding of [11C]suzetrigine to NaV1.8. Saturation binding assays revealed a Bmax = 93 fmol/mg and a KD = 0.1 nM, supporting the imageability of NaV1.8 in the brain using this tracer. In vivo PET imaging in rats demonstrated rapid and sufficient brain uptake but revealed unexpected tracer behavior: signal intensity markedly increased following pretreatment with either unlabeled suzetrigine or the P-gp inhibitor verapamil, and showed a slight increase after pretreatment with the heterologous NaV1.8 inhibitor A-803467. Detailed analysis of PET images, TACs, and normalized area-under-curve (AUC) values indicated that these atypical uptake patterns were primarily attributable to P-gp-mediated effects, although additional factors may also contribute. Conclusions: [11C]Suzetrigine exhibits high affinity, good brain uptake, and selective target engagement in vitro, supporting its potential as a first-in-class NaV1.8-PET tracer. However, in vivo performance is confounded by P-gp-mediated efflux and possibly other mechanisms that limit accurate quantification of NaV1.8 in the living brain. These findings underscore the critical role of efflux transporters in CNS radiotracer development and highlight the need for design strategies that mitigate P-gp interaction when targeting ion channels in the brain. Future studies will include imaging under constant P-gp inhibition, arterial blood sampling for radiometabolite analysis and full kinetic modeling, and evaluation in non-human primates to assess translational feasibility.

13 May 2026 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
SDSayani Das
Sayani Das
JSJacob Cyert Simon
Jacob Cyert Simon
MDMiranda Dawson
Miranda Dawson
VSVinay K. Sharma
Vinay K. Sharma
SASamira M. Abozeid
Samira M. Abozeid
AJAlan Jasanoff
Alan Jasanoff

4 April 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
MDMiranda Dawson
Miranda Dawson
SBSarah Bricault
Sarah Bricault
PHPeter Harvey
Peter Harvey
AWAgata Wisniowska
Agata Wisniowska
HWHe Wei
He Wei
AJAlan Jasanoff
Alan Jasanoff
Achieving widespread delivery of pharmacological agents beyond the blood-brain barrier (BBB) remains a formidable challenge in preclinical and clinical research. Here we quantitatively evaluate and compare three strategies for brain-wide delivery that employ transient BBB disruption or infusion via the cerebrospinal fluid (CSF) in rats. Using molecular magnetic resonance imaging (MRI) techniques, we find that the three techniques produce spatially differentiated labeling patterns, with the most homogeneous delivery produced either using chemically mediated or unfocused ultrasound-based BBB manipulation methods. Contrast enhancement distributions are similar following chemical and ultrasound procedures, but differ notably from the results of intra-CSF infusion. Delivery efficiency using the two BBB disruption methods also correlates inversely with a marker of tight junction density, suggesting that common factors determine susceptibility to these techniques. Our study thus documents the spatial variation of BBB properties across the brain while offering guidance about brain-wide application of molecular technologies in neuroscience and neuromedicine.